(CGON) CG Oncology, Common stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.551m USD | Total Return: 149.4% in 12m
Avg Turnover: 50.7M
Qual. Beats: -1
Rev. Trend: 99.6%
Qual. Beats: 0
Warnings
High Debt while negative Cash Flow
Beneish M-Score 0.91 > -1.5 - likely earnings manipulation
Altman Z'' -7.15 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec, an oncolytic immunotherapy designed for the treatment of bladder cancer. The firm primarily targets Non-Muscle Invasive Bladder Cancer (NMIBC), specifically focusing on patients who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. Its pipeline includes multiple Phase 2 and Phase 3 clinical trials evaluating cretostimogene both as a monotherapy and in combination treatments.
The company operates within the biotechnology sector, where business models typically rely on high research and development (R&D) expenditures and the successful navigation of multi-phase FDA regulatory approvals before achieving commercial revenue. Oncolytic immunotherapy represents a specialized niche in oncology that utilizes engineered viruses to selectively infect and kill cancer cells while stimulating a systemic immune response.
Investors looking for deeper technical analysis and valuation metrics for biotech firms may find ValueRay to be a useful resource for further research. Headquartered in Irvine, California, CG Oncology was founded in 2010 and transitioned from its original name, Cold Genesys, Inc., in 2020.
- Clinical data readouts from phase 3 BOND-003 trial drive investor sentiment
- FDA approval timeline for cretostimogene grenadenorepvec determines commercial viability
- Market penetration within BCG-unresponsive bladder cancer segment dictates revenue potential
- Strategic partnerships or acquisition interest impact long-term valuation and capital
- R&D expenditure and cash burn rates influence future equity financing needs
| Net Income: -186.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -2.84 > 1.0 |
| NWC/Revenue: 21.0k% < 20% (prev 102k%; Δ -81.5k% < -1%) |
| CFO/TA -0.14 > 3% & CFO -160.0m > Net Income -186.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 31.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.5m) vs 12m ago 10.93% < -2% |
| Gross Margin: -50.05% > 18% (prev 0.99%; Δ -5.10k% > 0.5%) |
| Asset Turnover: 0.54% > 50% (prev 0.09%; Δ 0.45% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 1.10b - Total Current Liabilities 35.2m) / Total Assets 1.14b |
| B: -0.39 (Retained Earnings -439.2m / Total Assets 1.14b) |
| C: -0.21 (EBIT TTM -200.2m / Avg Total Assets 931.7m) |
| D: -10.10 (Book Value of Equity -439.2m / Total Liabilities 43.5m) |
| Altman-Z'' = -7.15 = D |
| DSRI: 0.48 (Receivables 1.27m/345k, Revenue 5.07m/662k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.34 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 7.66 (Revenue 5.07m / 662k) |
| TATA: -0.02 (NI -186.7m - CFO -160.0m) / TA 1.14b) |
| Beneish M = 0.91 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 64.59 with a total of 628,940 shares traded.
Over the past week, the price has changed by -4.00%,
over one month by -8.06%,
over three months by +10.19% and
over the past year by +149.42%.
CG Oncology, Common stock has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy CGON.
- StrongBuy: 5
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 90.3 | 39.8% |
P/B = 5.084
Revenue TTM = 5.07m USD
EBIT TTM = -200.2m USD
EBITDA TTM = -198.0m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 1.07m USD (from shortTermDebt, last quarter)
Debt = 12.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.58m
Net Debt = -1.06b USD (calculated: Debt 12.2m - CCE 1.08b)
Enterprise Value = 4.49b USD (5.55b + Debt 12.2m - CCE 1.08b)
Interest Coverage Ratio = unknown (Ebit TTM -200.2m / Interest Expense TTM 0.0)
EV/FCF = -27.96x (Enterprise Value 4.49b / FCF TTM -160.4m)
FCF Yield = -3.58% (FCF TTM -160.4m / Enterprise Value 4.49b)
FCF Margin = -3.16k% (FCF TTM -160.4m / Revenue TTM 5.07m)
Net Margin = -3.68k% (Net Income TTM -186.7m / Revenue TTM 5.07m)
Gross Margin = -50.05% ((Revenue TTM 5.07m - Cost of Revenue TTM 7.61m) / Revenue TTM)
Gross Margin QoQ = -173.5% (prev -25.50%)
Tobins Q-Ratio = 3.95 (Enterprise Value 4.49b / Total Assets 1.14b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 12.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -158.2m (EBIT -200.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 31.30 (Total Current Assets 1.10b / Total Current Liabilities 35.2m)
Debt / Equity = 0.01 (Debt 12.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 5.37 (negative EBITDA) (Net Debt -1.06b / EBITDA -198.0m)
Debt / FCF = 6.63 (negative FCF - burning cash) (Net Debt -1.06b / FCF TTM -160.4m)
Total Stockholder Equity = 800.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.04% (Net Income -186.7m / Total Assets 1.14b)
RoE = -15.06% (Net Income TTM -186.7m / Total Stockholder Equity 1.24b)
RoCE = -16.11% (EBIT -200.2m / Capital Employed (Equity 1.24b + L.T.Debt 3.00m))
RoIC = -15.08% (negative operating profit) (NOPAT -158.2m / Invested Capital 1.05b)
WACC = 10.68% (E(5.55b)/V(5.56b) * Re(10.70%) + D(12.2m)/V(5.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 11.14%
[DCF] Fair Price = unknown (Cash Flow -160.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.01 | # QB: -1
Revenue Correlation: 99.62 | Revenue CAGR: 345.0% | SUE: 0.83 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=-9.23% | Revisions=N/A | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=-5.34% | Revisions=+33% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.62 | Chg30d=-9.06% | Revisions=+14% | GrowthEPS=-25.8% | GrowthRev=+190.4%
EPS next Year (2027-12-31): EPS=-2.70 | Chg30d=-35.68% | Revisions=-14% | GrowthEPS=-3.3% | GrowthRev=+670.5%
[Analyst] Revisions Ratio: +33%